Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 15.83 USD 0.06% Market Closed
Market Cap: 2B USD
Have any thoughts about
Neogenomics Inc?
Write Note

Intrinsic Value

The intrinsic value of one NEO stock under the Base Case scenario is 12.15 USD. Compared to the current market price of 15.83 USD, Neogenomics Inc is Overvalued by 23%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NEO Intrinsic Value
12.15 USD
Overvaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Neogenomics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NEO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NEO?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Neogenomics Inc

Provide an overview of the primary business activities
of Neogenomics Inc.

What unique competitive advantages
does Neogenomics Inc hold over its rivals?

What risks and challenges
does Neogenomics Inc face in the near future?

Summarize the latest earnings call
of Neogenomics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Neogenomics Inc.

Provide P/S
for Neogenomics Inc.

Provide P/E
for Neogenomics Inc.

Provide P/OCF
for Neogenomics Inc.

Provide P/FCFE
for Neogenomics Inc.

Provide P/B
for Neogenomics Inc.

Provide EV/S
for Neogenomics Inc.

Provide EV/GP
for Neogenomics Inc.

Provide EV/EBITDA
for Neogenomics Inc.

Provide EV/EBIT
for Neogenomics Inc.

Provide EV/OCF
for Neogenomics Inc.

Provide EV/FCFF
for Neogenomics Inc.

Provide EV/IC
for Neogenomics Inc.

Show me price targets
for Neogenomics Inc made by professional analysts.

What are the Revenue projections
for Neogenomics Inc?

How accurate were the past Revenue estimates
for Neogenomics Inc?

What are the Net Income projections
for Neogenomics Inc?

How accurate were the past Net Income estimates
for Neogenomics Inc?

What are the EPS projections
for Neogenomics Inc?

How accurate were the past EPS estimates
for Neogenomics Inc?

What are the EBIT projections
for Neogenomics Inc?

How accurate were the past EBIT estimates
for Neogenomics Inc?

Compare the revenue forecasts
for Neogenomics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Neogenomics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Neogenomics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Neogenomics Inc compared to its peers.

Compare the P/E ratios
of Neogenomics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Neogenomics Inc with its peers.

Analyze the financial leverage
of Neogenomics Inc compared to its main competitors.

Show all profitability ratios
for Neogenomics Inc.

Provide ROE
for Neogenomics Inc.

Provide ROA
for Neogenomics Inc.

Provide ROIC
for Neogenomics Inc.

Provide ROCE
for Neogenomics Inc.

Provide Gross Margin
for Neogenomics Inc.

Provide Operating Margin
for Neogenomics Inc.

Provide Net Margin
for Neogenomics Inc.

Provide FCF Margin
for Neogenomics Inc.

Show all solvency ratios
for Neogenomics Inc.

Provide D/E Ratio
for Neogenomics Inc.

Provide D/A Ratio
for Neogenomics Inc.

Provide Interest Coverage Ratio
for Neogenomics Inc.

Provide Altman Z-Score Ratio
for Neogenomics Inc.

Provide Quick Ratio
for Neogenomics Inc.

Provide Current Ratio
for Neogenomics Inc.

Provide Cash Ratio
for Neogenomics Inc.

What is the historical Revenue growth
over the last 5 years for Neogenomics Inc?

What is the historical Net Income growth
over the last 5 years for Neogenomics Inc?

What is the current Free Cash Flow
of Neogenomics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Neogenomics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Neogenomics Inc

Current Assets 584.2m
Cash & Short-Term Investments 387.9m
Receivables 146.6m
Other Current Assets 49.8m
Non-Current Assets 1.1B
PP&E 175.8m
Intangibles 879.2m
Other Non-Current Assets 4.1m
Current Liabilities 290m
Accounts Payable 17.2m
Accrued Liabilities 71.7m
Other Current Liabilities 201m
Non-Current Liabilities 437.4m
Long-Term Debt 339.6m
Other Non-Current Liabilities 97.9m
Efficiency

Earnings Waterfall
Neogenomics Inc

Revenue
628.3m USD
Cost of Revenue
-360.4m USD
Gross Profit
267.9m USD
Operating Expenses
-355.9m USD
Operating Income
-88m USD
Other Expenses
9.5m USD
Net Income
-78.5m USD

Free Cash Flow Analysis
Neogenomics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NEO Profitability Score
Profitability Due Diligence

Neogenomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
31/100
Profitability
Score

Neogenomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

NEO Solvency Score
Solvency Due Diligence

Neogenomics Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Negative Net Debt
45/100
Solvency
Score

Neogenomics Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NEO Price Targets Summary
Neogenomics Inc

Wall Street analysts forecast NEO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEO is 21.17 USD with a low forecast of 16.16 USD and a high forecast of 31.5 USD.

Lowest
Price Target
16.16 USD
2% Upside
Average
Price Target
21.17 USD
34% Upside
Highest
Price Target
31.5 USD
99% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NEO?

Click here to dive deeper.

Dividends

Neogenomics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for NEO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

NEO News

Other Videos

Profile

Neogenomics Inc Logo
Neogenomics Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

2B USD

Dividend Yield

0%

Description

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,000 full-time employees. The company went IPO on 2012-12-10. The firm operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The company operates testing laboratories in United States, Europe and Asia.

Contact

FLORIDA
Fort Myers
9490 Neogenomics Way
+12397680600.0
neogenomics.com

IPO

2012-12-10

Employees

2 000

Officers

CEO & Director
Mr. Christopher Michael Smith BSc
Chief Financial Officer
Mr. Jeffrey S. Sherman M.B.A.
President of Advanced Diagnostics
Mr. Vishal Sikri
President & COO of Informatics
Ms. Melody Harris Esq., J.D.
Chief Commercial Officer
Mr. Warren Stone
Chief Accounting Officer
Mr. Gregory D. Aunan
Show More
Vice President of Investor Relations & Communications
Ms. Kendra Sweeney
Executive VP of Business Development, General Counsel & Corporate Secretary
Ms. Alicia Olivo
Chief Compliance Officer
Mr. Hutan Hashemi J.D.
Chief Medical Officer
Dr. Derek Lyle M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one NEO stock?

The intrinsic value of one NEO stock under the Base Case scenario is 12.15 USD.

Is NEO stock undervalued or overvalued?

Compared to the current market price of 15.83 USD, Neogenomics Inc is Overvalued by 23%.

Back to Top